Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

Phase 1, pharmacogenomic, dose‐expansion study of pegargiminase plus pemetrexed and cisplatin in patients with ASS1‐deficient non‐squamous non‐small cell lung cancer

Abstract Introduction We evaluated the arginine‐depleting enzyme pegargiminase (ADI‐PEG20; ADI) with pemetrexed (Pem) and cisplatin (Cis) (ADIPemCis) in ASS1‐deficient non‐squamous non‐small cell lung cancer (NSCLC) via a phase 1 dose‐expansion trial with exploratory biomarker analysis. Methods Sixt...

Full description

Bibliographic Details
Main Authors: Peter W. Szlosarek, Akhila G. Wimalasingham, Melissa M. Phillips, Peter E. Hall, Pui Ying Chan, John Conibear, Louise Lim, Sukaina Rashid, Jeremy Steele, Paula Wells, Chiung‐Fang Shiu, Chih‐Ling Kuo, Xiaoxing Feng, Amanda Johnston, John Bomalaski, Stephen Ellis, Marianne Grantham, Michael Sheaff
Format: Article
Language:English
Published: Wiley 2021-10-01
Series:Cancer Medicine
Subjects:
ADIPemCis
arginine
arginine deiminase
ASS1
KRAS
non‐squamous NSCLC
Online Access:https://doi.org/10.1002/cam4.4196

Internet

https://doi.org/10.1002/cam4.4196

Similar Items